Biologic impact of interferon antibodies, and complexities in assessing their clinical significance

Neurology

Volumn 61, Issue 9 SUPPL. 5, 2003, Pages

  Rudick, Richard A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON ANTIBODY; BETA1A INTERFERON; INTERFERON ANTIBODY; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; CONFERENCE PAPER; CORRELATION FUNCTION; DRUG ANTIGENICITY; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENCE RISK;

EID: 0242404136     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000092363.40248.0e     Document Type: Conference Paper

References (6)

1. The IFNB Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
2. PRISMS-4. Long-term efficacy of interferon-beta-1a in relapsing MS 1. Neurology 2001;56:1628-1636.
3. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) [see comments]. Neurology 1998;50:1266-1272.
4. Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999;52:1239-1243.
5. Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003;60:634-639.
6. Knobler RL, Panitch HS, Braheny SL, et al. Clinical trial of natural alpha interferon in multiple sclerosis. Ann NY Acad Sci 1984;436:382-388.